Technical Analysis for BNTC - Benitec Biopharma Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Historical BNTC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| 200 DMA Support | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 20 DMA Support | Bullish | -9.02% | |
| Wide Bands | Range Expansion | -9.02% | |
| 200 DMA Support | Bullish | -3.27% | |
| 20 DMA Support | Bullish | -3.27% | |
| Narrow Range Bar | Range Contraction | -3.27% | |
| NR7 | Range Contraction | -3.27% | |
| Wide Bands | Range Expansion | -3.27% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 200 DMA Support | about 13 hours ago |
| Fell Below Previous Day's Low | about 14 hours ago |
| 20 DMA Support | about 17 hours ago |
| Down 5% | about 18 hours ago |
| Fell Below 20 DMA | about 18 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 10/28/2021
Benitec Biopharma Limited Description
Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Biopharmaceutical Biology Pain Genetics Chemotherapy Small Cell Lung Cancer Macular Degeneration Related Macular Degeneration Hepatitis B Gene Expression Dystrophy Genetic Engineering Hepatitis C Muscular Dystrophy Wet Age Related Macular Degeneration Huntington's Disease HIV/Aids Retinitis RNA Rna Interference Retinitis Pigmentosa Clinical Applications Gene Silencing Ai Technology Chronic And Life Threatening Conditions Oculopharyngeal Muscular Dystrophy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.39 |
| 52 Week Low | 2.3 |
| Average Volume | 3,216,842 |
| 200-Day Moving Average | 4.72 |
| 50-Day Moving Average | 4.28 |
| 20-Day Moving Average | 4.95 |
| 10-Day Moving Average | 5.02 |
| Average True Range | 0.79 |
| ADX | 40.24 |
| +DI | 32.92 |
| -DI | 14.76 |
| Chandelier Exit (Long, 3 ATRs ) | 8.14 |
| Chandelier Exit (Short, 3 ATRs ) | 5.21 |
| Upper Bollinger Band | 7.41 |
| Lower Bollinger Band | 2.48 |
| Percent B (%b) | 0.46 |
| BandWidth | 99.60 |
| MACD Line | 0.25 |
| MACD Signal Line | 0.30 |
| MACD Histogram | -0.0519 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.70 | ||||
| Resistance 3 (R3) | 5.79 | 5.57 | 5.54 | ||
| Resistance 2 (R2) | 5.57 | 5.32 | 5.52 | 5.49 | |
| Resistance 1 (R1) | 5.15 | 5.17 | 5.04 | 5.06 | 5.43 |
| Pivot Point | 4.93 | 4.93 | 4.87 | 4.88 | 4.93 |
| Support 1 (S1) | 4.51 | 4.68 | 4.40 | 4.42 | 4.05 |
| Support 2 (S2) | 4.29 | 4.53 | 4.24 | 3.99 | |
| Support 3 (S3) | 3.87 | 4.29 | 3.94 | ||
| Support 4 (S4) | 3.78 |
